The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Randomized Phase III Trial of Gemcitabine Compared With Pegylated Liposomal Doxorubicin in Patients With Platinum-Resistant Ovarian Cancer
Open accessAbstract
Purpose: Ovarian cancer (OC) patients experiencing progressive disease (PD) within 6 months of platinum-based therapy in the primary setting are considered platinum resistant (Pt-R). Currently, pegylated liposomal doxorubicin (PLD) is a standard of care for treatment of recurrent Pt-R disease. On the basis of promising phase II results, gemcitabine was compared with PLD for efficacy and safety in taxane-pretreated Pt-R OC patients. Patients and Methods: Patients (n = 195) with Pt-R OC were randomly assigned to either gemcitabine 1,000 mg/m 2 (days 1 and 8; every 21 days) or PLD 50 mg/m 2 (day 1; every 28 days) until PD or undue toxicity. Optional cross-over therapy was allowed at PD or at withdrawal because of toxicity. Primary end point was progression-free survival (PFS). Additional end points included tumor response, time to treatment failure, survival, and quality of life. Results: In the gemcitabine and PLD groups, median PFS was 3.6 v 3.1 months; median overall survival was 12.7 v 13.5 months; overall response rate (ORR) was 6.1% v 8.3%; and in the subset of patients with measurable disease, ORR was 9.2% v 11.7%, respectively. None of the efficacy end points showed a statistically significant difference between treatment groups. The PLD group experienced significantly more hand-foot syndrome and mucositis; the gemcitabine group experienced significantly more constipation, nausea/vomiting, fatigue, and neutropenia but not febrile neutropenia. Conclusion: Although this was not designed as an equivalency study, gemcitabine and PLD seem to have a comparable therapeutic index in this population of Pt-R taxane-pretreated OC patients. Single-agent gemcitabine may be an acceptable alternative to PLD for patients with Pt-R OC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., Smigal, C., & Thun, M. J. (2006) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.56.2.106 · Cited by 5,314
Greenlee, R. T., Hill-Harmon, M. B., Murray, T., & Thun, M. (2001) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.51.1.15 · Cited by 3,288
Gordon, A. N., Fleagle, J. T., Guthrie, D., Parkin, D. E., Gore, M. E., & Lacave, A. J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.14.3312 · Cited by 1,211
Self-citationEdwards, B. K., Brown, M. L., Wingo, P. A., Howe, H. L., Ward, E., Ries, L. A. G., Schrag, D., Jamison, P. M., Jemal, A., Wu, X. C., et al. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji289 · Cited by 952
Tables of the number of patients required in clinical trials using the logrank test
Freedman, L. S. (1982) · Statistics in Medicine · doi:10.1002/sim.4780010204 · Cited by 718
Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer.
ten Bokkel Huinink, W., Gore, M., Carmichael, J., Gordon, A., Malfetano, J., Hudson, I., Broom, C., Scarabelli, C., Davidson, N., Spanczynski, M., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.6.2183 · Cited by 663
Self-citationGordon, A. N., Granai, C. O., Rose, P. G., Hainsworth, J., Lopez, A., Weissman, C., Rosales, R., & Sharpington, T. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.17.3093 · Cited by 336
Self-citationBruera, E., Strasser, F., Palmer, J. L., Willey, J., Calder, K., Amyotte, G., & Baracos, V. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.01.101 · Cited by 287
Reliability and validity of the functional assessment of cancer therapy-ovarian
Basen-Engquist, K., Bodurka-Bevers, D., Fitzgerald, M. A., Webster, K., Cella, D., Hu, S., & Gershenson, D. M. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.6.1809 · Cited by 280
Use of CA-125 to Define Progression of Ovarian Cancer in Patients With Persistently Elevated Levels
Rustin, G. J. S., Marples, M., Nelstrop, A. E., Mahmoudi, M., & Meyer, T. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.20.4054 · Cited by 201
Systemic Therapy for Ovarian Cancer: Current Status and New Treatments
Ozols, R. F. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2006.03.011 · Cited by 188
Piccart, M. J., Green, J. A., Lacave, A. J., Reed, N., Vergote, I., Benedetti-Panici, P., Bonetti, A., Kristeller-Tome, V., Fernandez, C. M., Curran, D., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.6.1193 · Cited by 159
Markman, M., KENNEDY, A. W., Webster, K. D., Peterson, G., Kulp, B., & Belinson, J. L. (2000) · Gynecologic Oncology · doi:10.1006/gyno.2000.5921 · Cited by 155
Rosenberg, P., Andersson, H., Boman, K., Ridderheim, M., Sorbe, B., Puistola, U., & Parö, G. (2002) · Acta Oncologica · doi:10.1080/028418602320404998 · Cited by 137
Friedlander, M. L., Millward, M., Bell, D., Bugat, R., Harnett, P. R., Moreno, J. A., Campbell, L., Varette, C., Ripoche, V., & Kayitalire, L. (1998) · Annals of Oncology · doi:10.1023/a:1008469212268 · Cited by 137
Huinink, W. T. B., Lane, S. R., & Ross, G. A. (2003) · Annals of Oncology · doi:10.1093/annonc/mdh025 · Cited by 122
Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer
Markman, M. M., Webster, K. D., Zanotti, K. M., Kulp, B., Peterson, G., & Belinson, J. L. (2003) · Gynecologic Oncology · doi:10.1016/s0090-8258(03)00399-8 · Cited by 109
Gore, M. E., Oza, A. M., Rustin, G. J. S., Malfetano, J. H., Calvert, H., Clarke‐Pearson, D. L., Carmichael, J., Ross, G. A., Beckman, R., & Fields, S. Z. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00188-5 · Cited by 106
Phase II study of gemcitabine in recurrent platinum-and paclitaxel-resistant ovarian cancer
D’Agostino, G., Amant, F. C., Berteloot, P., Scambia, G., & Vergote, I. B. (2003) · Gynecologic Oncology · doi:10.1016/s0090-8258(03)00011-8 · Cited by 103
Rose, P. G., Mossbruger, K., Fusco, N. L., Smrekar, M., Eaton, S., & Rodriguez, M. J. (2002) · Gynecologic Oncology · doi:10.1006/gyno.2002.6850 · Cited by 102
Bolis, G., Scarfone, G., Giardina, G., Villa, A., Mangili, G., Melpignano, M., Presti, M., Tateo, S., Franchi, M. P., & Parazzini, F. (2001) · Gynecologic Oncology · doi:10.1006/gyno.2001.6151 · Cited by 86
Buda, A. A., Floriani, I., Rossi, R., Colombo, N., Torri, V., Conte, P., Fossati, R., Ravaioli, A., & Mangioni, C. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601787 · Cited by 80
Progress in the Management of Gynecologic Cancer: Consensus Summary Statement
Cannistra, S. A., Bast, R. C., Berek, J. S., Bookman, M. A., Crum, C. P., DePriest, P. D., Garber, J. E., Koh, W.-J., Markman, M., McGuire, W. P., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.003 · Cited by 53
Cited by
Pujade-Lauraine, E., Hilpert, F., Weber, B., Reuss, A., Poveda, A., Kristensen, G., Sorio, R., Vergote, I., Witteveen, P., Bamias, A., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.4489 · Cited by 1,622
Hamanishi, J., Mandai, M., Ikeda, T., Minami, M., Kawaguchi, A., Murayama, T., Kanai, M., Mori, Y., Matsumoto, S., Chikuma, S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.3397 · Cited by 1,180
Nichols, J. W., & Bae, Y. H. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.03.057 · Cited by 834
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 4.2016
Ettinger, D. S., Wood, D. E., Akerley, W., Bazhenova, L. A., Borghaei, H., Camidge, D. R., Cheney, R. T., Chirieac, L. R., D'Amico, T. A., Dilling, T. J., et al. (2016) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2016.0031 · Cited by 736
Hennessy, B. T., Coleman, R. L., & Markman, M. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61338-6 · Cited by 640
Metadata
- Authors
- Mutch, D. G., Orlando, M., Goss, T., Teneriello, M. G., Gordon, A. N., McMeekin, S. D., Wang, Y., Scribner, D. R., Marciniack, M., Naumann, R. W., & Secord, A. A.
- Venue
- Journal of Clinical Oncology
- Published
- 2007-07-01
- Volume
- 25
- Issue
- 19
- Pages
- 2811-2818
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2107457010
- Cited by
- 426
- References
- 26
- FWCI
- 20.77
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.